Research Progress of IDH Mutation in Acute Myeloid Leukemia--Review.
10.19746/j.cnki.issn.1009-2137.2025.05.043
- Author:
Hui-Rong WU
1
;
Juan CHENG
1
Author Information
1. The First Clinical Medical College of Lanzhou University,Lanzhou 730700, Gansu Province, China.
- Publication Type:English Abstract
- Keywords:
acute myeloid leukemia
- MeSH:
Humans;
Isocitrate Dehydrogenase/genetics*;
Leukemia, Myeloid, Acute/genetics*;
Mutation;
Prognosis
- From:
Journal of Experimental Hematology
2025;33(5):1534-1537
- CountryChina
- Language:Chinese
-
Abstract:
Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults. Isocitrate dehydrogenase (IDH) is a key enzyme in the tricarboxylic acid cycle and one of the common mutated genes in AML. Although the 2022 version of the ELN guidelines suggests that IDH mutations cannot be used as a separate prognostic stratification indicator, multiple studies have indicated that IDH mutations have prognostic significance for AML. Early identification of IDH mutations and selection of appropriate treatment options are crucial. This review summarizes the research progress on the characteristics, carcinogenic mechanisms, prognosis of IDH mutations in AML patients, and treatment options, in order to provide reference for further improving the prognosis of IDH -mutated AML patients.
